Physician Search

This will be a Phase 1 Open-Label, dose escalation and expansion study of MT-0169 (an Engineered toxin body (ETB) in patients with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma. MT-0169 is an investigational drug that recognizes and binds to the CD38 receptor, which may be found on the surface of multiple myeloma and non-Hodgkin lymphoma cancer cells. It delivers a dose of a modified toxin that kills these cells.

This trial studies how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for women with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.

This randomized clinical phase III trial studies how well web-based physical activity intervention works in improving long term health in children and adolescents with cancer. Regular physical activity after receiving treatment for cancer may help to maintain a healthy weight and improve energy levels and overall health.

This trial uses fluid measurements of the arm and MRI to determine biomarkers of lymphatic dysfunction in patients with breast cancer. Studying the lymphatic system (the part of your body that helps to process and clear waste products) in different ways will help doctors understand more about lymphedema (excess fluid after lymph nodes are removed) and help with prevention and management of lymphedema in patients with breast cancer.

Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg / m2 250 mg / m2 BID (strata 1, 2, 3, and 4) OR 2500 mg / m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and / or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.

This randomized phase III trial studies digital tomosynthesis mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment.

This phase II trial studies how well artificial tears works in reducing radioiodine levels in the nasolacrimal duct system in patients with thyroid carcinoma following radioiodine therapy. Radioactive iodine therapy for thyroid carcinoma has been associated with nasolacrimal duct obstruction. Artificial tears may dilute the amount of radioactive iodine in the tears of the eyes, thus decreasing uptake by the cells lining the nasolacrimal duct system.

This trial investigates how well near infrared autofluorescence imaging works in identifying parathyroid glands during surgery to remove one or more parathyroid glands (parathyroidectomy). The parathyroid gland is an important organ in the neck that regulates calcium levels in the body. Thus, it is essential for a surgeon to correctly identify this organ when performing parathyroid surgeries. By assisting the surgeon in correctly identifying a diseased parathyroid gland, the 'PTeye' near infrared autofluorescence imaging device may improve the quality of the operation performed on the patient. This trial may determine if the PTeye truly benefits a patient undergoing surgery for parathyroid disease or not.

This trial studies how well infrared autofluorescence via PTeye works in detecting parathyroid glands during total thyroid surgery. Located closely to the thyroid gland are the parathyroid glands, which are important organs that regulate calcium levels in the body. Thus, it is essential for a surgeon to correctly identify this structure when performing a thyroid surgery. PTeye may help surgeon to identify and preserve healthy parathyroid glands during surgery. By assisting the surgeon in correctly identifying parathyroid glands, this device may improve the quality of the operation performed on the patient.